Evidence map›Paper›PMID 38140008›Full record

ArticlePharmaceutics2023

Enhancement of Skin Permeability Prediction through PBPK Modeling, Bayesian Inference, and Experiment Design.

Abdullah Hamadeh, Abdulkarim Najjar, John Troutman, Andrea Edginton

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Abdullah HamadehSchool of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada.ORCID 0000-0002-9419-1797
Abdulkarim NajjarBeiersdorf AG, 20245 Hamburg, Germany.ORCID 0000-0003-4620-9830
John TroutmanThe Procter & Gamble Company, Mason, OH 45040, USA.ORCID 0000-0003-0722-5387
Andrea EdgintonSchool of Pharmacy, University of Waterloo, Kitchener, ON N2G 1C5, Canada.ORCID 0000-0002-9014-1653
University of Waterloo · CABeiersdorf (Germany) · DEProcter & Gamble (United States) · US

Funding

Beiersdorf (Germany) NAProcter & Gamble (United States) NA
6 · The paper itself

Abstract

Physiologically based pharmacokinetic (PBPK) models of skin absorption are a powerful resource for estimating drug delivery and chemical risk of dermatological products. This paper presents a PBPK workflow for the quantification of the mechanistic determinants of skin permeability and the use of these quantities in the prediction of skin absorption in novel contexts. A state-of-the-art mechanistic model of dermal absorption was programmed into an open-source modeling framework. A sensitivity analysis was performed to identify the uncertain compound-specific, individual-specific, and site-specific model parameters that impact permeability. A Bayesian Markov Chain Monte Carlo algorithm was employed to derive distributions of these parameters given in vitro experimental permeability measurements. Extrapolations to novel contexts were generated by simulating the model following its update with samples drawn from the learned distributions as well as parameters that represent the intended scenario. This algorithm was applied multiple times, each using a unique set of permeability measurements sourced under experimental contexts that differ in terms of the compound, vehicle pH, skin sample anatomical site, and the number of compounds under which each subject's skin samples were tested. Among the data sets used in this study, the highest accuracy and precision in the extrapolated permeability was achieved in those that include measurements conducted under multiple vehicle pH levels and in which individual subjects' skin samples are tested under multiple compounds. This work thus identifies factors for consideration in the design of experiments for the purpose of training dermal models to robustly estimate drug delivery and chemical risk.

Indexed as

Bayesiandermalexperiment designmechanisticmodelingpharmacokineticsskin

Identifiers

PMID38140008
PMCPMC10747907
OpenAlexW4388971725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.